Nifty Pharma's June quarter earnings may decline due to fading gains from generic drug launches, with currency depreciation expected to offset some of the impact.

India

Who

Macquarie, Kunal Dhamesha, Dr. Reddy's, Biocon

What

When

Fri, 17 Jul 2026 00:00:00 GMT · 10h 12m ago

Where

India ·

Why

Currency depreciation and the absence of key generic product launches are expected to negatively impact earnings, although a stronger biologics pipeline for Biocon and future semaglutide opportunities offer some offset.

The Frontline Impact

How this affects you

The forecast suggests a potential downturn in earnings for India's pharmaceutical sector in the June quarter, influenced by currency fluctuations and shifts in generic product revenue streams.

Story chain

1 event in this thread

No related history yet - this is the origin event.

Verified Sources & Citations

CNBC TV18
https://www.cnbctv18.com/market/earnings/nifty-pharma-april-june-2026-q1-earnings-fall-16-percent-generic-drug-boost-fades-biocon-drl-divis-labs-sun-torrent-aurobindo-lupin-apollo-ent-metropolis-semaglutide-19947973.htm
HIGH

Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.